Completed |
NCT04191148 |
Urinary Tract Infections, UTI |
E.coli genome |
LBP-EC01 |
CRISPR-Cas3 |
Phase I |
crPhage cocktail - In-vivo |
https://clinicaltrials.gov/ct2/show/record/NCT04191148 |
Unknown |
NCT03728322 |
Thalassemia Genetic Diseases |
Hemoglobin
Subunit Beta (HBB) |
No |
CRISPR-Cas9 |
Phase I |
Ex-vivo |
https://clinicaltrials.gov/ct2/show/record/NCT03728322 |
Active, not recruiting |
NCT03655678 |
Thalassemia Genetic Diseases |
BAF Chromatin Remodeling Complex Subunit 11A (BCL11A) |
CTX001 |
CRISPR-Cas9 |
Phase II/III |
Electroporation - Ex-vivo |
https://clinicaltrials.gov/ct2/show/record/NCT03655678 |
Active not recruiting |
NCT04205435 |
Beta-Thalassemia |
Hemoglobin
Subunit Beta (HBB) |
β-globin restored autologous HSC |
CRISPR-Cas9 |
Phase I/II |
Electroporation - Ex-vivo |
https://clinicaltrials.gov/ct2/show/record/NCT04205435 |
Enrolling by invitation |
NCT05143307 |
HIV |
Undisclosed |
EBT-101 |
CRISPR-Cas9 |
Phase I |
AAV9 - In-vivo |
https://clinicaltrials.gov/ct2/show/NCT05143307 |
Concerned |
2018-001320-19 |
Sickle Cell Disease, Haematological
Diseases, Haemoglobinopathies |
HBB |
CTX001 |
CRISPR-Cas9 |
Phase I/II |
Electroporation - Ex-vivo |
https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001320-19/BE#A |
Active |
NCT03745287 |
Sickle Cell Disease, Haematological Diseases,
Haemoglobinopathies |
BAF Chromatin Remodeling Complex Subunit 11A
(BCL11A) |
CTX001 |
CRISPR-Cas9 |
Phase II/ III |
Electroporation -
Ex-vivo |
https://clinicaltrials.gov/ct2/show/record/NCT03745287 |
Active |
ChiCTR2100052858 |
Transfusion Dependent Beta-Thalassaemia, TDT |
Undisclosed |
RM-001 |
CRISPR-Cas9 |
Phase I |
Undisclosed- Ex-vivo |
https://www.chictr.org.cn/hvshowproject.aspx?id=106695 |
Active |
NCT04037566 |
Leukemia Lymphocytic Acute in Relapse, Leukemia
Lymphocytic Acute (All) Refractory Lymphoma, B-Cell, CD19 Positive, ALL |
CD19 molecule , HPK1 hematopoietic progenitor kinase 1 (also known as
MAP4K1) |
Cyclophosphamide/ Fludarabine |
CRISPR-Cas9 |
Phase I |
Lentivirus (LV) and electroporation - Ex-vivo |
https://clinicaltrials.gov/ct2/show/record/NCT04037566 |
Active |
NCT04560790 |
Herpes Simplex Virus Refractory Keratitis |
UL8/UL29 |
BD111 Adult single group Dose |
CRISPR-Cas9 |
Phase I/II |
mRNA transfection - In-vivo |
https://clinicaltrials.gov/ct2/show/record/NCT04560790 |
Active |
NCT03872479 |
Blindness, Leber Congenital Amaurosis |
Centrosomal Protein 290 (CEP290) |
EDIT-101 |
CRISPR-Cas9 |
Phase I/II |
Adeno-associated virus (AAV5) - In-vivo |
https://clinicaltrials.gov/ct2/show/record/NCT03872479 |
Active |
NCT05210530 |
Type 1 Diabetes, T1D |
- |
VCTX210A unit |
CRISPR-Cas9 |
Phase I |
Ex-vivo |
https://clinicaltrials.gov/ct2/show/NCT05210530 |
Active |
NCT05120830 |
Hereditary Angioedema, HAE |
Kallikrein B1
(KLKB1) |
Biological NTLA-2002 |
CRISPR-Cas9 |
Phase I/II |
Lipid Nano
Particles (LNPs) - In-vivo |
https://clinicaltrials.gov/ct2/show/NCT05120830 |
Active |
NCT04601051 |
Hereditary Transthyretin Amyloidosis, ATTR |
Transthyretin (TTR) |
NTLA-2001 |
CRISPR-Cas9 |
Phase I |
Lipid
Nanoparticles (LNP) - In-vivo |
https://clinicaltrials.gov/ct2/show/record/NCT04601051 |